Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL328025 | 0.76 | ALDH1A1 (0.36) | ALDH1A1GSK3BGRIN2B | |
| SCHEMBL279992 | 0.72 | DAO (0.44) | ALDH1A1MEN1DAOKMT2A | |
| SCHEMBL280176 | 0.61 | HCAR2 (0.47) | MEN1KMT2A | |
| SCHEMBL12858787 | 0.58 | — | — | |
| SCHEMBL31479102 | 0.54 | HTT (0.33) | — | |
| SCHEMBL279616 | 0.52 | RAB9A (0.49) | ALDH1A1KDM4EMEN1MAPTDAO | |
| SCHEMBL279607 | 0.51 | HPGD (0.55) | ALDH1A1KDM4EDAOKMT2A | |
| SCHEMBL6795205 | 0.51 | GSK3B (1.00) | ALDH1A1GSK3BKDM4EMEN1MAPT | |
| SCHEMBL15483706 | 0.50 | MAPT (0.55) | ALDH1A1GSK3BKDM4EMEN1MAPT | |
| SCHEMBL6399748 | 0.50 | ALDH1A1 (0.56) | ALDH1A1KDM4EMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8134013-B2 | Amide compound and thrombopoietin receptor activator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, PTAFR, MPL | ALDH1A1 2047/4885GSK3B 2918/4885KDM4E 4435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.